{"id":"ts-172","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL5910057","moleculeType":null,"molecularWeight":"407.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TS-172 acts as a selective serotonin receptor antagonist, which is believed to contribute to its therapeutic effects. The exact mechanism of action is not fully understood, but it is thought to involve modulation of the serotonin system.","oneSentence":"TS-172 is a small molecule that targets the serotonin receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:00.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT07231029","phase":"PHASE1","title":"A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment","status":"RECRUITING","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-12-23","conditions":"Patients With Mild or Moderate Hepatic Impairment","enrollment":24},{"nctId":"NCT07285291","phase":"PHASE3","title":"A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders","status":"RECRUITING","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":"Hyperphosphatemia Patients on Hemodialysis","enrollment":100},{"nctId":"NCT07285304","phase":"PHASE3","title":"A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis","status":"RECRUITING","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-12-01","conditions":"Hyperphosphatemia Patients on Hemodialysis","enrollment":300},{"nctId":"NCT06745531","phase":"PHASE3","title":"A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-01-06","conditions":"Hyperphosphatemia Patients on Hemodialysis","enrollment":101},{"nctId":"NCT07084961","phase":"PHASE1","title":"A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-08-05","conditions":"Healthy Adult Male Subjects","enrollment":16},{"nctId":"NCT06745518","phase":"PHASE2","title":"A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-01-06","conditions":"Hyperphosphatemia Patients on Hemodialysis","enrollment":62},{"nctId":"NCT06837155","phase":"PHASE1","title":"A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-03-03","conditions":"Healthy Volunteers","enrollment":52},{"nctId":"NCT06837142","phase":"PHASE1","title":"A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-03-11","conditions":"Healthy Male Subjects","enrollment":30},{"nctId":"NCT06849778","phase":"PHASE1","title":"An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2025-03-22","conditions":"Patients on Hemodialysis","enrollment":7},{"nctId":"NCT06596356","phase":"PHASE1","title":"A Mass Balance Study of TS-172 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2024-09-26","conditions":"Healthy Male Subjects","enrollment":6},{"nctId":"NCT05699239","phase":"PHASE2","title":"A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2023-02-08","conditions":"Hyperphosphatemia Patients on Hemodialysis","enrollment":326},{"nctId":"NCT04979572","phase":"PHASE1","title":"A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2021-08-16","conditions":"Healthy Adult Subjects","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TS-172","genericName":"TS-172","companyName":"Taisho Pharmaceutical Co., Ltd.","companyId":"taisho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TS-172 is a small molecule that targets the serotonin receptor. Used for Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}